- Polymerase chain reaction (PCR) is used to rapidly make millions to billions of copies of a specific DNA sample and only requires a very small sample of DNA to amplify it large enough for detailed study.
- ColoAlert utilizes proprietary methods to analyse the cell DNA for specific tumor markers.
- ColoAlert is designed to detect tumor DNA and detect 85% of colorectal cancer cases - often in the earliest stages of the disease.*
- Ease-of-use drives ongoing patient adherence as the ColoAlert method requires very small samples compared to ColoGuard.
*Dollinger MM et al. (2018), ClinLab 64 (10), 1719-1730 and Gies et al. (2018). Gastroenterology 154 (1), 93-104.and Cooper GS et al. (2018). Dig Dis Sci. 63 (6), 1449-1453. * 18 study centres, 566 patients, 10/2018 and Amani et al. (2019). Clin. Lab. 65:1751-1754.
Grab Sources And More Here: MYNZ Website. MYNZ Presentation. -----
And as I mentioned above, (Nasdaq: MYNZ) could earn some near term breakout buzz due to these potential catalysts. Check them out...
#1. MYNZ Potential Catalyst - A Really Low Float Situation Could Create A Volatile Scenario (In A Blink).
According to the Yahoo Finance website, MYNZ has a low float.
In fact, the website reports this profile to have approximately 2.76Mn shares in its float.
Why is that important? It's important on one crucial level. Volatility potential.
If the company provides more positive company news in the first half of 2025, could it create a near term spark? -----
#2. MYNZ Potential Catalyst - An Analyst Target May Suggest 250+% Potential Upside From Current Levels.
Back in February, at least one analyst recognized MYNZ to potentially be undervalued.
That analyst, Michael Okunewitch, from Maxim Group, tagged MYNZ with a rather strong price target.
With a target of $14.00, MYNZ has a potential upside of well over 250% from this Friday's closing valuation. -----
#3. MYNZ Potential Catalyst - A Key Clinical Study Takes A Major Step Forward As Mainz Biomed Enrolls 1st Patient. Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study
BERKELEY, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the first patient has been enrolled in eAArly DETECT 2, a feasibility study to evaluate the Company’s next-generation colorectal cancer (CRC) test. ...
...
Read the full article here. -----
#4. MYNZ Potential Catalyst - A "Groundbreaking" Discovery Could Lead To Company's Test Becoming The Most Accurate Pancreatic Cancer Screening Test On The Market.
Mainz Biomed and Liquid Biosciences Make Groundbreaking Discovery of mRNA Biomarkers for Blood Based Detection of Pancreatic Cancer
From the article:
“Securing the exclusive rights to license this portfolio of novel biomarkers is a major milestone and extension of our previously announced PancAlert program. It provides us with an extraordinary opp. in the early detection and diagnosis of one of the most challenging cancers to treat. We believe that this achievement marks a paradigm shift in how we can detect pancreatic cancer,” said Mainz Biomed’s CEO, Guido Baechler.
Read the full article here. -----
#5. MYNZ Potential Catalyst - Mainz Biomed Positions To Advance Commercial Development Of ColoAlert Through Agreement With Quest Diagnostics.
Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test
BERKELEY, Calif. and MAINZ, Germany, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today an agreement with Quest Diagnostics (NYSE:DGX), a leading provider of diagnostic information services, to support commercialization of Mainz Biomed’s NextGen screening test for colorectal cancer.
...
Read the full article here. -----
(Nasdaq: MYNZ) Recap - These Potential Breakout Catalysts Could Be Worth Watching Closely
#1. A Really Low Float Situation Could Create A Volatile Scenario (In A Blink).
#2. An Analyst Target May Suggest 250+% Potential Upside From Current Levels.
#3. A Key Clinical Study Takes A Major Step Forward As Mainz Biomed Enrolls 1st Patient.
#4. A "Groundbreaking" Discovery Could Lead To Company's Test Becoming The Most Accurate Pancreatic Cancer Screening Test On The Market.
#5. Mainz Biomed Positions To Advance Commercial Development Of ColoAlert Through Agreement With Quest Diagnostics. -----
Coverage is officially initiated on Mainz Biomed N.V. (Nasdaq: MYNZ).
I'll be in touch again soon with more. Keep your eyes peeled.
Sincerely, FierceAnalyst | Jaks Swift Editorial Writer
(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)
*FierceInvestor (FierceInvestor . com) is owned by SWN Media LLC, a limited liability company. Data is provided from third-party sources and FierceInvestor ("FI") is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. We do not provide personalized fin-ancial advice, are not finan-cial advisors, and our opinions are not suitable for all in-vest-ors.
Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 04/27/2025 and ending on 04/28/2025 to publicly disseminate information about (MYNZ:US) via digital communications. Under this agreement, SWN Media LLC has been paid seventeen thousand five hundred USD (“Funds”). To date, including under the previously described agreement, SWN Media LLC has been paid ninety thousand USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did not receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.
Neither SWN Media LLC, TD Media LLC and their member own shares of (MYNZ:US).
Please see important disclosure information here: https://fierceinvestor.com/disclosure/mynz-zr9ty/#details | 
Tidak ada komentar:
Posting Komentar